Contraindicated in:
Use Cautiously in:
CNS: mood/behavior effects, NEUROLEPTIC MALIGNANT SYNDROME, weakness, drowsiness.
CV: hypotension, QT interval prolongation, TORSADES DE POINTES.
Derm: skin discoloration.
EENT: blurred vision, dry eyes.
Endo: galactorrhea (women).
GI: constipation, dry mouth, ↓ appetite, nausea, vomiting, weight loss.
GU: ↓libido, erectile dysfunction.
Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia.
Neuro: akathisia, parkinsonism, dystonic reactions, tardive dyskinesia, akinesia.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Absorption: 50% absorbed following oral administration.
Distribution: Unknown.
Metabolism/Excretion: Undergoes extensive first-pass hepatic metabolism, primarily by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6 enzyme systems; the CYP2D6 enzyme system exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly ↑ pimozide concentrations and an ↑ risk of adverse effects). Some metabolites have CNS activity.
Half-life: 29111 hr.